In July 2024, the author visited Vitalia, a pop-up city in the Honduran special economic zone Próspera on Roatán, which promotes the idea of “making death optional” by accelerating anti-aging research.

Vitalia’s pitch: bypass conventional U.S. regulatory hurdles (three trial phases; ~90% attrition; “valley of death”) to move from Phase-1-like safety to market far faster and cheaper.

Próspera (founded 2017; backed by tech investors) functions as a business-run ZEDE where firms can choose a regulatory framework (common law, OECD country rules, or a new system) and operate with mandatory insurance instead of traditional approval.

Vitalia co-founders Niklas Anzinger and Laurence Ion frame the core problem as regulation, citing “Eroom’s Law” (shrinking drug productivity per R&D dollar). They argue efficacy can be shown post-commercialization.

Critics counter that biology—not just regulation—is the hard part. Philosopher Alex John London notes the FDA already lets developers pick the “best case” for trials; if efficacy can’t be shown there, why expect success elsewhere?

On the ground, Vitalia’s futuristic renderings clashed with unfinished reality (incomplete housing, improvised labs, mundane logistics like medical care for a scorpion sting handled off-site).

Despite the “Make Death Optional” branding, there was little peer-reviewed, placebo-controlled research visible. Attendees skewed toward tech/crypto rather than lab scientists; many were in ideation, not execution.

Example: Minicircle conducted a follistatin gene-therapy study (muscle growth in healthy people) with 43 participants via a local clinic/IRB, then offered injections starting at ~$25,000.

Bioethicists and scientists questioned the rigor: commercialization immediately after Phase-1-like safety, self-published data, clinic-linked IRB, potential conflicts of interest, and difficulty ensuring standardized follow-up in a tourism setting.

The legal ground shifted: in Sept 2024, Honduras’ Supreme Court declared ZEDEs unconstitutional. Vitalia’s founders split; the project rebranded as Infinita City. Infrastructure improved somewhat, but trial activity remained sparse (Minicircle’s study; a small new trial by Unlimited Bio).

Investors remain wary about how U.S. regulators would treat Próspera-generated data. Meanwhile, some firms eye jurisdictions like the Bahamas or U.S. states (e.g., Montana’s SB535) that allow post-Phase-1 access.

Supporters say zones like Próspera can seed early safety signals, pressure the FDA to modernize, and enable pilot studies among informed, consenting adults. Detractors call it medical tourism and P.R., not science that generalizes.

Core concern persists: without robust, placebo-controlled efficacy trials, it’s hard to know if interventions work. The pipeline looks parallel and expensive rather than transformative.

Bottom line: regulatory shortcuts don’t solve the fundamental challenge—proving that therapies are safe, effective, and scalable. For now, Vitalia/Infinita resembles an experiment in governance and bio-commerce more than a repeatable engine for validated longevity breakthroughs.